ADVANZ PHARMA
ADVANZ PHARMA is a London-headquartered, privately held specialty pharmaceutical company that develops and commercialises innovative medicines, specialty generics, biosimilars, and originator brands across more than 90 countries, serving patients with hepatology, gastroenterology, anti-infective, critical care, endocrinology, oncology, CNS, and rare disease conditions.
- Company typePrivate
- Founded-
- HeadquartersLondon, United Kingdom
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What ADVANZ PHARMA does
ADVANZ PHARMA is a privately held, London-headquartered specialty pharmaceutical company that develops and commercialises complex medicines — innovative medicines, specialty generics, biosimilars, and originator brands — across therapeutic areas including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and rare diseases. Its operational footprint spans commercial sales in more than 90 countries, with a direct commercial presence in more than 20 markets across Europe, Canada, and Australia, complemented by a Centre of Excellence in Mumbai, India, and a global distribution and commercialisation partner network of more than 300 counterparties. Core recent assets include the Gobivaz (golimumab biosimilar to Simponi) and the Eylea (aflibercept) biosimilar pipeline built through a strategic co-development partnership with Alvotech, alongside a specialty generics portfolio (deferiprone, levothyroxine, methotrexate, lenalidomide, carbimazole, digoxin, chloromycetin, levofloxacin, omega-3-acid ethyl ester, emtricitabine/tenofovir, vernakalant) and originator brands such as Brinavess, Progynova, and Ilomedin.
The company monetises through pharmaceutical product sales under one-time licence economics, generating revenue from sales of its specialty, hospital, and rare disease medicines through both direct enterprise field sales in its owned geographies and channel/distributor partnerships elsewhere; pricing is not publicly disclosed. The parent entity, ADVANZ PHARMA CORP. Limited, is incorporated in Jersey, UK, with ADVANZ PHARMA Services (UK) Limited operating as a wholly-owned subsidiary in England. As of January 2026, the company is operating under a formal sale process pursuant to the UK City Code on Takeovers and Mergers, indicating active consideration of an ownership transition, and has recently executed portfolio-accretive deals including the December 2025 acquisition of Progynova/Cyclo-Progynova EMEA rights and global Ilomedin rights.
ADVANZ PHARMA firmographics
Firmographics- Name
- ADVANZ PHARMA
- Legal name
- ADVANZ PHARMA CORP. Limited
- Website
- https://concordiarxinternational.com
- Company type
- Private
- Operating status
- Operating
- Short description
- ADVANZ PHARMA is a London-headquartered, privately held specialty pharmaceutical company that develops and commercialises innovative medicines, specialty generics, biosimilars, and originator brands across more than 90 countries, serving patients with hepatology, gastroenterology, anti-infective, critical care, endocrinology, oncology, CNS, and rare disease conditions.
- Ownership category
- akta.pro rank
ADVANZ PHARMA industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Generic Hospital & Institutional Products (HLAIABAL)
Keywords
Where ADVANZ PHARMA is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
ADVANZ PHARMA business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
Revenue model
- Pharmaceutical Product Sales: Revenue generated from the sale of specialty, hospital, and rare disease medicines including innovative medicines, specialty generics, biosimilars, and originator brands.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
ADVANZ PHARMA product offering
Product offeringCore offering
ADVANZ PHARMA develops and commercialises specialty, hospital, and rare disease medicines, including innovative medicines, specialty generics, biosimilars, and originator brands. The portfolio spans therapeutic areas such as hepatology, rheumatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and rare diseases. The company acts as a partner of choice for innovative biopharma and pharmaceutical development companies across more than 90 countries globally.
Product overview
ADVANZ PHARMA is a global specialty pharmaceutical company that commercialises specialty, hospital, and rare disease medicines. The company's product portfolio comprises three main categories: innovative medicines, specialty generics & biosimilars, and originator brands. The portfolio covers therapeutic areas including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and rare diseases. The company is rapidly building a diverse biosimilars portfolio through a partnership with Alvotech, including products such as Gobivaz® (golimumab biosimilar) and Mynzepli (aflibercept biosimilar), aimed at expanding treatment options and reducing healthcare costs. The company operates with commercial sales in more than 90 countries globally.
Differentiator
Problem solved
Functional benefit
Brands
- Gobivaz: A biosimilar to Simponi (golimumab) developed in partnership with Alvotech, received marketing approval across the European Economic Area
- MYNZEPLI
- Brinavess
Companies that use ADVANZ PHARMA
Customer profileSegments1 record
ADVANZ PHARMA technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
ADVANZ PHARMA partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- AlvotechcoreADVANZ PHARMA partnered with Alvotech for the development and commercialisation of biosimilar products. The partnership includes Eylea (aflibercept) biosimilar and Gobivaz (golimumab biosimilar). Marketing approvals have been received for Gobivaz across the European Economic Area and from MHRA.
- Innovative Biopharma CompaniescoreADVANZ PHARMA partners with innovative biopharma and pharmaceutical development companies to bring medicines to patients worldwide. The company works with more than 300 partners in production, development, portfolio licensing, and commercialisation.
- Healthcare ProfessionalscoreADVANZ PHARMA engages with healthcare professionals for professional purposes including clinical trial participation, advisory engagements, scientific collaboration, and compliance with transparency obligations.
Scale indicators2 records
Recent moves6 records
Expansion highlights6 records
ADVANZ PHARMA competitors and assessment
Company assessmentDirect peers
- Alvotech: Biosimilar developer partnered with ADVANZ PHARMA on Eylea and Gobivaz, with overlapping focus on specialty biologic/biosimilar products and shared commercial economics in Europe and other ADVANZ markets.
- Hikma Pharmaceuticals: UK-headquartered specialty and generic pharmaceutical company with a comparable portfolio spanning specialty generics, hospital injectables, and biosimilars sold across Europe, the Middle East, and North America.
- Stada Arzneimittel: European-focused specialty generics and consumer healthcare company, similarly operating a partner-of-choice model for biosimilars and specialty products across hospital and retail channels.
- Mallinckrodt: Specialty pharmaceutical company with hospital-focused brands, specialty generics, and rare disease exposure — overlapping with ADVANZ's specialty, hospital, and rare disease therapeutic areas.
- Endo International: Specialty pharma with branded and generics portfolios spanning endocrinology, oncology, and rare diseases — directly comparable therapeutic-area coverage and product mix to ADVANZ PHARMA.
Broad incumbents
- Viatris: Large global pharmaceutical company with established specialty, biosimilar, and generics franchises across Europe and worldwide — a much broader incumbent but overlapping significantly with ADVANZ's product and market footprint.
- Sandoz (Novartis): Global leader in biosimilars and generics with significant European and global commercial reach, representing a much larger but directly comparable incumbent in the same biosimilar/specialty generic space.
- Teva Pharmaceutical Industries: Global specialty and generics powerhouse with European commercial scale and biosimilar capabilities — overlapping with ADVANZ's specialty generics and biosimilar portfolio across the same hospital and specialty channels.
Emerging players
- Glenmark Pharmaceuticals: India-based specialty generics and biosimilars player expanding in Europe and emerging markets, with comparable product categories though smaller commercial scale in ADVANZ's core European markets.
- Aspen Pharmacare: Global specialty and generics pharmaceutical company with European and emerging-market presence, comparable in therapeutic-area breadth though more concentrated in branded specialty and regional generics.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
ADVANZ PHARMA social profiles
Digital presenceADVANZ PHARMA compliance and trust
Trust signalCompliance4 records
ADVANZ PHARMA financial estimates
Financial estimateRevenue estimate
Valuation estimate
ADVANZ PHARMA leadership team
Management profileNumber of profiles
ADVANZ PHARMA subsidiaries and ownership
Company hierarchySubsidiaries1 record
ADVANZ PHARMA funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ADVANZ PHARMA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ADVANZ PHARMA
What does ADVANZ PHARMA do?
ADVANZ PHARMA develops and commercialises specialty, hospital, and rare disease medicines, including innovative medicines, specialty generics, biosimilars, and originator brands. The portfolio spans therapeutic areas such as hepatology, rheumatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and rare diseases. The company acts as a partner of choice for innovative biopharma and pharmaceutical development companies across more than 90 countries globally.
Is ADVANZ PHARMA a public or private company?
ADVANZ PHARMA is a private company. It is currently operating.
When was ADVANZ PHARMA founded?
ADVANZ PHARMA was founded in -1.
Where is ADVANZ PHARMA based?
ADVANZ PHARMA is headquartered in London, United Kingdom, in the Europe region.
How does ADVANZ PHARMA make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are ADVANZ PHARMA's main competitors?
Direct peers on record are Alvotech, Hikma Pharmaceuticals, Stada Arzneimittel, Mallinckrodt and Endo International. Broad incumbents are Viatris, Sandoz (Novartis) and Teva Pharmaceutical Industries. Emerging players are Glenmark Pharmaceuticals and Aspen Pharmacare.
Does ADVANZ PHARMA have an API?
No public API is recorded for ADVANZ PHARMA.
What industry is ADVANZ PHARMA in?
ADVANZ PHARMA's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.